Bibliography
- Peters A, Barendregt JJ, Willenkens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003;138:24-32
- Doggrell SA. Is rimonabant efficacious and safe in the treatment of obesity? Expert Opin Pharmacother 2008;9:2727-31
- Astrup A, Meier DH, Mikkelsen BO, et al. Weight loss produced in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring) 2008;16:1363-9
- Astrup A, Breum L, Jensen TJ, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13
- Thatte U. NS-2330 (Neurosearch). Curr Opin Investig Drugs 2001;2:1592-4
- Lehr T, Staab A, Tillman C, et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic pharmacodynamic modelling approach. Br J Pharmacol 2008;115:164-74
- Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, and anti-obesity drug with a novel mechanism of action. Obes Rev 2000;1:127-39
- Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:1706-43
- Available from: http://en.sanofi-aventis.com/binaries/20081105_rimonabant_en _tcm28-22682.pdf
- Swinburn BA, Carey D, Hills AP, et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab 2005;7:254-62